5166 related articles for article (PubMed ID: 3384660)
1. [Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Garbe C; Guenther-Eymann K; Stadler R; Orfanos CE
Hautarzt; 1988 Apr; 39(4):205-12. PubMed ID: 3384660
[TBL] [Abstract][Full Text] [Related]
2. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
4. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
5. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
6. [Therapy and prognosis of malignant melanoma of the skin].
Braun-Falco O; Landthaler M; Hölzel D; Konz B; Schmoeckel C
Dtsch Med Wochenschr; 1986 Nov; 111(46):1750-6. PubMed ID: 3780438
[TBL] [Abstract][Full Text] [Related]
7. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
8. [Results of a randomized polychemotherapy study in malignant melanoma].
Fiedler H; Hetschko I; Wohlrab W; Wozniak KD; Lübbe D; Taube KM
Hautarzt; 1990 Jul; 41(7):369-74. PubMed ID: 1698185
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
11. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
12. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
13. [Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity].
Huber R; Krüger I; Stützer H
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():118-21. PubMed ID: 9101808
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
Roses DF; Provet JA; Harris MN; Gumport SL; Dubin N
Ann Surg; 1985 Jan; 201(1):103-7. PubMed ID: 3966826
[TBL] [Abstract][Full Text] [Related]
16. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
19. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]